Introduction
CVD, dementia, MCI, cognitive impairment
CVD, BLOOD, ADVERSE EVENTS, CARDIOVASCULAR DISEASE
In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive (systolic blood pressure [SBP] goal <120 mm Hg) vs standard (SBP goal <140 mm Hg) treatment reduced the risk of a composite outcome of mild cognitive impairment (MCI) and probable dementia, in addition to cardiovascular disease (CVD) and all-cause mortality.Detecting patient characteristics associated with the greatest magnitude of cognitive benefit from intensive vs standard SBP treatment may help prioritize patients, as the intensive treatment component requires additional health care resources (clinical time, office and laboratory visits, and medications) and increases the risk of mostly mild, transient treatment-related adverse events.